Taiwan · Delayed Price · Currency is TWD PharmaEngine Statistics
Total Valuation
PharmaEngine has a market cap or net worth of TWD 10.22 billion. The enterprise value is 4.82 billion.
| Market Cap | 10.22B |
| Enterprise Value | 4.82B |
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | Aug 13, 2025 |
Share Statistics
PharmaEngine has 143.68 million shares outstanding. The number of shares has increased by 0.16% in one year.
| Current Share Class | 143.68M |
| Shares Outstanding | 143.68M |
| Shares Change (YoY) | +0.16% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 6.03% |
| Float | 93.43M |
Valuation Ratios
The trailing PE ratio is 6.28 and the forward PE ratio is 28.44.
| PE Ratio | 6.28 |
| Forward PE | 28.44 |
| PS Ratio | 4.12 |
| PB Ratio | 2.19 |
| P/TBV Ratio | 2.19 |
| P/FCF Ratio | 5.86 |
| P/OCF Ratio | 5.86 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.36, with an EV/FCF ratio of 2.76.
| EV / Earnings | 2.95 |
| EV / Sales | 1.94 |
| EV / EBITDA | 2.36 |
| EV / EBIT | 2.37 |
| EV / FCF | 2.76 |
Financial Position
The company has a current ratio of 5.38, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.38 |
| Quick Ratio | 5.34 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
| Interest Coverage | 16,767.21 |
Financial Efficiency
Return on equity (ROE) is 38.15% and return on invested capital (ROIC) is 29.62%.
| Return on Equity (ROE) | 38.15% |
| Return on Assets (ROA) | 25.53% |
| Return on Invested Capital (ROIC) | 29.62% |
| Return on Capital Employed (ROCE) | 43.55% |
| Revenue Per Employee | 56.39M |
| Profits Per Employee | 37.06M |
| Employee Count | 44 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.68 |
Taxes
In the past 12 months, PharmaEngine has paid 432.52 million in taxes.
| Income Tax | 432.52M |
| Effective Tax Rate | 20.97% |
Stock Price Statistics
The stock price has decreased by -32.86% in the last 52 weeks. The beta is 0.18, so PharmaEngine's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -32.86% |
| 50-Day Moving Average | 67.41 |
| 200-Day Moving Average | 84.81 |
| Relative Strength Index (RSI) | 58.39 |
| Average Volume (20 Days) | 663,788 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEngine had revenue of TWD 2.48 billion and earned 1.63 billion in profits. Earnings per share was 11.33.
| Revenue | 2.48B |
| Gross Profit | 2.43B |
| Operating Income | 2.03B |
| Pretax Income | 2.06B |
| Net Income | 1.63B |
| EBITDA | 2.03B |
| EBIT | 2.03B |
| Earnings Per Share (EPS) | 11.33 |
Balance Sheet
The company has 5.40 billion in cash and 4.81 million in debt, giving a net cash position of 5.40 billion or 37.57 per share.
| Cash & Cash Equivalents | 5.40B |
| Total Debt | 4.81M |
| Net Cash | 5.40B |
| Net Cash Per Share | 37.57 |
| Equity (Book Value) | 4.66B |
| Book Value Per Share | 32.42 |
| Working Capital | 4.63B |
Cash Flow
In the last 12 months, operating cash flow was 1.74 billion and capital expenditures -269,000, giving a free cash flow of 1.74 billion.
| Operating Cash Flow | 1.74B |
| Capital Expenditures | -269,000 |
| Free Cash Flow | 1.74B |
| FCF Per Share | 12.14 |
Margins
Gross margin is 98.05%, with operating and profit margins of 81.77% and 65.72%.
| Gross Margin | 98.05% |
| Operating Margin | 81.77% |
| Pretax Margin | 83.15% |
| Profit Margin | 65.72% |
| EBITDA Margin | 81.84% |
| EBIT Margin | 81.77% |
| FCF Margin | 70.29% |
Dividends & Yields
This stock pays an annual dividend of 6.00, which amounts to a dividend yield of 8.51%.
| Dividend Per Share | 6.00 |
| Dividend Yield | 8.51% |
| Dividend Growth (YoY) | 300.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 13.21% |
| Buyback Yield | -0.16% |
| Shareholder Yield | 8.27% |
| Earnings Yield | 15.96% |
| FCF Yield | 17.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2017. It was a forward split with a ratio of 1.1999616012.
| Last Split Date | Jul 26, 2017 |
| Split Type | Forward |
| Split Ratio | 1.1999616012 |
Scores
PharmaEngine has an Altman Z-Score of 10.62 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.62 |
| Piotroski F-Score | 6 |